BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced that members of the company’s management team will present at the following investor conferences:


9th Annual Evercore Healthcare Conference
Presentation Date/Time: December 1, 2026, at 9:10 a.m. ET
Piper Sandler 38th Annual Healthcare Conference
Presentation Date/Time: December 2, 2026, at 10:30 a.m. ET
Interested parties can access live audio webcasts of these presentations via the Investor Relations section of the company’s website at www.immunome.com. Replay webcasts will be available for approximately 30 days following the live presentations.
About Immunome, Inc.
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates (ADCs). Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA and an MAA has been validated by the EMA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; IM-3050, a clinical-stage FAP-targeted radioligand therapy; and IM-1340, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets.
Investor Contact
Max Rosett
Chief Financial Officer
investors@immunome.com
| Nov-18 | |
| Nov-09 | |
| Nov-06 | |
| Nov-04 | |
| Nov-02 | |
| Oct-30 | |
| Oct-26 | |
| Oct-06 | |
| Sep-30 | |
| Sep-08 | |
| Sep-02 | |
| Aug-11 | |
| Aug-06 | |
| Jul-20 | |
| Jul-08 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite